A股異動 | 莎普愛思升停 與恒道醫藥簽署《技術轉讓(技術祕密)合同》
莎普愛思(603168.SH)今日一字升停,報11.54元,股價創2022年1月底以來新高,總市值42.99億元。莎普愛思日前公吿稱,近日公司與南京恒道醫藥科技股份有限公司(簡稱“恒道醫藥”)簽署了《技術轉讓(技術祕密)合同》,恒道醫藥將其擁有的鹽酸毛果芸香鹼滴眼液藥物臨牀試驗批件項目的技術祕密、所有權(包括但不限於生產、銷售等權利)轉讓予公司。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.